An Update on Impacts of Epigallocatechin Gallate Co-administration in Modulating Pharmacokinetics of Statins, Calcium Channel Blockers, and Beta-blockers
Planta Med DOI: 10.1055/a-2111-7319Brewed green tea, green tea extract, and its primary active compound, epigallocatechin gallate, may interact with drugs and alter the drugʼs therapeutic effectiveness, ultimately leading to
therapeutic failure or drug overdose. Several isolated reports have claimed that epigallocatechin gallate is the main active ingredient that causes these effects. While a few studies aimed
to uncover evidence of epigallocatechin gallate-drug interactions, no study has thoroughly and collectively reviewed them. Epigallocatechin gallate is a potential cardioprotective agent used
by many p...
Source: Planta Medica - July 14, 2023 Category: Drugs & Pharmacology Authors: Siew-Keah, Lee Jie, Tan Hong Ang-Lim, Chua Bin, Liew Kai Yik-Ling, Chew Tags: Reviews Source Type: research
Statins protect mice from high-decibel noise-induced hearing loss
In this study in CBA/CaJ mice, hearing was also assessed in the contralateral cochlea 1-4 weeks after noise exposure. At two weeks post exposure, ABR thresholds at 4, 8, 12, 16, and 32 kHz were elevated, as expected, in the noise+carrier alone treated mice by approximately 9-, 17-, 41-, 29-, and 34-dB, respectively. Threshold elevations were smaller in mice treated with noise+fluvastatin to about 2-, 6-, 20-,12- and 12-dB respectively. Survival of inner hair cell synapses were not protected by fluvastatin over these frequencies. Lovastatin delivered by gavage showed lower threshold shifts than with carrier alone. These dat...
Source: Biomedicine and pharmacotherapy = Biomedecine and pharmacotherapie - July 12, 2023 Category: Drugs & Pharmacology Authors: Fr édéric Dépreux Lyubov Czech Hunter Young Claus-Peter Richter Yingjie Zhou Donna S Whitlon Source Type: research
Statins protect mice from high-decibel noise-induced hearing loss
In this study in CBA/CaJ mice, hearing was also assessed in the contralateral cochlea 1-4 weeks after noise exposure. At two weeks post exposure, ABR thresholds at 4, 8, 12, 16, and 32 kHz were elevated, as expected, in the noise+carrier alone treated mice by approximately 9-, 17-, 41-, 29-, and 34-dB, respectively. Threshold elevations were smaller in mice treated with noise+fluvastatin to about 2-, 6-, 20-,12- and 12-dB respectively. Survival of inner hair cell synapses were not protected by fluvastatin over these frequencies. Lovastatin delivered by gavage showed lower threshold shifts than with carrier alone. These dat...
Source: Biomedicine and pharmacotherapy = Biomedecine and pharmacotherapie - July 12, 2023 Category: Drugs & Pharmacology Authors: Fr édéric Dépreux Lyubov Czech Hunter Young Claus-Peter Richter Yingjie Zhou Donna S Whitlon Source Type: research
Statins protect mice from high-decibel noise-induced hearing loss
In this study in CBA/CaJ mice, hearing was also assessed in the contralateral cochlea 1-4 weeks after noise exposure. At two weeks post exposure, ABR thresholds at 4, 8, 12, 16, and 32 kHz were elevated, as expected, in the noise+carrier alone treated mice by approximately 9-, 17-, 41-, 29-, and 34-dB, respectively. Threshold elevations were smaller in mice treated with noise+fluvastatin to about 2-, 6-, 20-,12- and 12-dB respectively. Survival of inner hair cell synapses were not protected by fluvastatin over these frequencies. Lovastatin delivered by gavage showed lower threshold shifts than with carrier alone. These dat...
Source: Biomedicine and pharmacotherapy = Biomedecine and pharmacotherapie - July 12, 2023 Category: Drugs & Pharmacology Authors: Fr édéric Dépreux Lyubov Czech Hunter Young Claus-Peter Richter Yingjie Zhou Donna S Whitlon Source Type: research
Fluvastatin: a choice for COVID-19 associated mucormycosis management
Curr Med Chem. 2023 Jul 6. doi: 10.2174/0929867331666230706152616. Online ahead of print.ABSTRACTSARS-CoV-2 invades the respiratory tract epithelium and can result in systemic inflammation prior to an infection caused by either bacteria or fungus. COVID-19-associated mucormycosis (CAM) is a serious condition that can occur during the time of the disease due to increased administration of corticosteroids. Various studies have suggested that statins may improve clinical outcomes in COVID-19 patients. According to several preclinical reports, fluvastatin was shown to exert direct and indirect synergistic antifungal activity. ...
Source: Current Medicinal Chemistry - July 7, 2023 Category: Chemistry Authors: Alireza Tavakkoli Thomas P Johnston Amirhossein Sahebkar Source Type: research
Fluvastatin: a choice for COVID-19 associated mucormycosis management
Curr Med Chem. 2023 Jul 6. doi: 10.2174/0929867331666230706152616. Online ahead of print.ABSTRACTSARS-CoV-2 invades the respiratory tract epithelium and can result in systemic inflammation prior to an infection caused by either bacteria or fungus. COVID-19-associated mucormycosis (CAM) is a serious condition that can occur during the time of the disease due to increased administration of corticosteroids. Various studies have suggested that statins may improve clinical outcomes in COVID-19 patients. According to several preclinical reports, fluvastatin was shown to exert direct and indirect synergistic antifungal activity. ...
Source: Current Medicinal Chemistry - July 7, 2023 Category: Chemistry Authors: Alireza Tavakkoli Thomas P Johnston Amirhossein Sahebkar Source Type: research
Fluvastatin: a choice for COVID-19 associated mucormycosis management
Curr Med Chem. 2023 Jul 6. doi: 10.2174/0929867331666230706152616. Online ahead of print.ABSTRACTSARS-CoV-2 invades the respiratory tract epithelium and can result in systemic inflammation prior to an infection caused by either bacteria or fungus. COVID-19-associated mucormycosis (CAM) is a serious condition that can occur during the time of the disease due to increased administration of corticosteroids. Various studies have suggested that statins may improve clinical outcomes in COVID-19 patients. According to several preclinical reports, fluvastatin was shown to exert direct and indirect synergistic antifungal activity. ...
Source: Current Medicinal Chemistry - July 7, 2023 Category: Chemistry Authors: Alireza Tavakkoli Thomas P Johnston Amirhossein Sahebkar Source Type: research
Fluvastatin: a choice for COVID-19 associated mucormycosis management
Curr Med Chem. 2023 Jul 6. doi: 10.2174/0929867331666230706152616. Online ahead of print.ABSTRACTSARS-CoV-2 invades the respiratory tract epithelium and can result in systemic inflammation prior to an infection caused by either bacteria or fungus. COVID-19-associated mucormycosis (CAM) is a serious condition that can occur during the time of the disease due to increased administration of corticosteroids. Various studies have suggested that statins may improve clinical outcomes in COVID-19 patients. According to several preclinical reports, fluvastatin was shown to exert direct and indirect synergistic antifungal activity. ...
Source: Current Medicinal Chemistry - July 7, 2023 Category: Chemistry Authors: Alireza Tavakkoli Thomas P Johnston Amirhossein Sahebkar Source Type: research
The appropriateness of the use of statins for the secondary and primary prevention of atherosclerotic cardiovascular disease: a cross-sectional study from Jordan
CONCLUSIONS: The use of statins was not in concordance with the guidelines. Many of the patients surveyed were undertreated and adequate follow-up to identify the extent of patients' compliance and response was missing.PMID:37401284 | DOI:10.26355/eurrev_202306_32785 (Source: European Review for Medical and Pharmacological Sciences)
Source: European Review for Medical and Pharmacological Sciences - July 4, 2023 Category: Drugs & Pharmacology Authors: L Gharaibeh S Al Zoubi H Sartawi D Ayyad M Al-Hawamdeh R Alrashdan Source Type: research
The appropriateness of the use of statins for the secondary and primary prevention of atherosclerotic cardiovascular disease: a cross-sectional study from Jordan
CONCLUSIONS: The use of statins was not in concordance with the guidelines. Many of the patients surveyed were undertreated and adequate follow-up to identify the extent of patients' compliance and response was missing.PMID:37401284 | DOI:10.26355/eurrev_202306_32785 (Source: Pharmacological Reviews)
Source: Pharmacological Reviews - July 4, 2023 Category: Drugs & Pharmacology Authors: L Gharaibeh S Al Zoubi H Sartawi D Ayyad M Al-Hawamdeh R Alrashdan Source Type: research
The appropriateness of the use of statins for the secondary and primary prevention of atherosclerotic cardiovascular disease: a cross-sectional study from Jordan
CONCLUSIONS: The use of statins was not in concordance with the guidelines. Many of the patients surveyed were undertreated and adequate follow-up to identify the extent of patients' compliance and response was missing.PMID:37401284 | DOI:10.26355/eurrev_202306_32785 (Source: European Review for Medical and Pharmacological Sciences)
Source: European Review for Medical and Pharmacological Sciences - July 4, 2023 Category: Drugs & Pharmacology Authors: L Gharaibeh S Al Zoubi H Sartawi D Ayyad M Al-Hawamdeh R Alrashdan Source Type: research
The appropriateness of the use of statins for the secondary and primary prevention of atherosclerotic cardiovascular disease: a cross-sectional study from Jordan
CONCLUSIONS: The use of statins was not in concordance with the guidelines. Many of the patients surveyed were undertreated and adequate follow-up to identify the extent of patients' compliance and response was missing.PMID:37401284 | DOI:10.26355/eurrev_202306_32785 (Source: Atherosclerosis)
Source: Atherosclerosis - July 4, 2023 Category: Cardiology Authors: L Gharaibeh S Al Zoubi H Sartawi D Ayyad M Al-Hawamdeh R Alrashdan Source Type: research
The appropriateness of the use of statins for the secondary and primary prevention of atherosclerotic cardiovascular disease: a cross-sectional study from Jordan
CONCLUSIONS: The use of statins was not in concordance with the guidelines. Many of the patients surveyed were undertreated and adequate follow-up to identify the extent of patients' compliance and response was missing.PMID:37401284 | DOI:10.26355/eurrev_202306_32785 (Source: European Review for Medical and Pharmacological Sciences)
Source: European Review for Medical and Pharmacological Sciences - July 4, 2023 Category: Drugs & Pharmacology Authors: L Gharaibeh S Al Zoubi H Sartawi D Ayyad M Al-Hawamdeh R Alrashdan Source Type: research
